secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2024-12-03T23:59:59+00:00
Accession:  0000950170-24-132874
Event type: litigation
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron wins patent lawsuit against Fresenius Kabi over CINVANTI; generic blocked until 2035
--------------------------------------------------------------------------------

- Court ruled Heron's U.S. Patent Nos. 9,561,229 and 9,974,794 valid and infringed by Fresenius Kabi's proposed generic CINVANTI.
- Effective date of any FDA approval for Fresenius Kabi's ANDA cannot be earlier than September 18, 2035 (patent expiration).
- Ruling follows partial summary judgment for infringement in May 2024 and four-day bench trial in June 2024.
- Heron will submit proposed final judgment by December 9, 2024.
- This protects CINVANTI revenue from generic competition until patents expire in 2035.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000095017024132874/0000950170-24-132874-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000095017024132874/hrtx-20241203.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-132874

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer